Why a single chart is not evidence
Online calculators often assume the stated vial amount is accurate and the material behaves like another formulation. Those assumptions are not established by a generic product page.
A concentration calculation can describe arithmetic, but it cannot validate identity, sterility, excipients, compatibility, or stability. This page therefore does not convert a research-vendor vial into administration instructions.
What a defensible record includes
- A lot-specific certificate of analysis with identity and assay information.
- A product-specific specification that identifies the formulation and fill amount.
- Stability and handling evidence for that exact formulation.
- A documented laboratory protocol appropriate to the approved research setting.
What this evidence review covers
Explain why BPC-157 vendor vials do not share one validated mixing chart.
- Minimum evidence for product-specific preparation
- Mass versus concentration
- No syringe-unit calculator
- Retail-vial versus study-material boundary
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
source limitation
The human pilot does not validate preparation of unrelated vendor vials.
regulatory
FDA identifies API-characterization and peptide-impurity concerns.
| Evidence class | What the source supports |
|---|---|
| source limitation | The human pilot does not validate preparation of unrelated vendor vials. |
| regulatory | FDA identifies API-characterization and peptide-impurity concerns. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Evidence class: primary uncontrolled human pilot. What it supports: Two previously exposed adults; short-term vital-sign and laboratory observations; no efficacy endpoint.
What it does not establish: General safety, any efficacy claim, a dosage schedule, a monitoring protocol, or other routes.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
How much water for 5mg?
Do not answer generically; the question assumes a verified product and compatible validated process.
Can a calculator make it safe?
No. Arithmetic cannot establish identity, sterility, stability, or suitability.
What remains unresolved
- No manufacturer-validated preparation file.
- No stability/sterility data for tracked products.